keyword
https://read.qxmd.com/read/38651033/the-tumor-immune-microenvironment-is-associated-with-recurrence-in-early-stage-lung-adenocarcinoma
#1
JOURNAL ARTICLE
Hiroaki Kanemura, Toshihide Yokoyama, Ryu Nakajima, Atsushi Nakamura, Hiroaki Kuroda, Yoshitaka Kitamura, Hiroyasu Shoda, Nobuaki Mamesaya, Yoshihiro Miyata, Tatsuro Okamoto, Kyoichi Okishio, Masahide Oki, Yuichi Sakairi, Toyofumi Fengshi Chen-Yoshikawa, Tadashi Aoki, Tatsuo Ohira, Isao Matsumoto, Kiyonobu Ueno, Takuro Miyazaki, Haruhisa Matsuguma, Hideoki Yokouchi, Tomoyuki Otani, Akihiko Ito, Kazuko Sakai, Yasutaka Chiba, Kazuto Nishio, Nobuyuki Yamamoto, Isamu Okamoto, Kazuhiko Nakagawa, Masayuki Takeda
INTRODUCTION: Immune checkpoint inhibitors have recently been approved for the treatment of early-stage NSCLC in the perioperative setting on the basis of phase 3 trials. However, the characteristics of such patients who are susceptible to recurrence after adjuvant chemotherapy or who are likely to benefit from postoperative immunotherapy have remained unclear. METHODS: This biomarker study (WJOG12219LTR) was designed to evaluate cancer stem cell markers (CD44 and CD133), programmed death-ligand 1 (PD-L1) expression on tumor cells, CD8 expression on tumor-infiltrating lymphocytes, and tumor mutation burden in completely resected stage II to IIIA NSCLC with the use of archived DNA and tissue samples from the prospective WJOG4107 trial...
April 2024: JTO clinical and research reports
https://read.qxmd.com/read/38649280/tumor-agnostic-transcriptome-based-classifier-identifies-spatial-infiltration-patterns-of-cd8-t-cells-in-the-tumor-microenvironment-and-predicts-clinical-outcome-in-early-phase-and-late-phase-clinical-trials
#2
JOURNAL ARTICLE
Andreas Roller, Iakov I Davydov, Petra C Schwalie, Martha L Serrano-Serrano, Astrid Heller, Nicolas Staedler, Cláudia S Ferreira, Gabriele Dietmann, Irina Klaman, Alberto Valdeolivas, Konstanty Korski, Michael A Cannarile
BACKGROUND: The immune status of a patient's tumor microenvironment (TME) may guide therapeutic interventions with cancer immunotherapy and help identify potential resistance mechanisms. Currently, patients' immune status is mostly classified based on CD8+tumor-infiltrating lymphocytes. An unmet need exists for comparable and reliable precision immunophenotyping tools that would facilitate clinical treatment-relevant decision-making and the understanding of how to overcome resistance mechanisms...
April 22, 2024: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/38646528/itgal-expression-in-non-small-cell-lung-cancer-tissue-and-its-association-with-immune-infiltrates
#3
JOURNAL ARTICLE
Ruihao Zhang, Guangsheng Zhu, Zaishan Li, Zhenzhen Meng, Hua Huang, Chen Ding, Yanan Wang, Chen Chen, Yongwen Li, Hongyu Liu, Jun Chen
BACKGROUND: Integrin subunit alpha L (ITGAL) encodes an integrin component of LFA-1 and is a membrane receptor molecule widely expressed on leukocytes. It plays a key role in the interaction between white blood cells and other cells. There was a significant correlation between the expression of ITGAL and the tumor microenvironment in a number of cancers. However, experimental studies targeting ITGAL and immune cell infiltration in non-small-cell lung cancer (NSCLC) and the response to immune checkpoint inhibitor therapy are lacking...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38640930/25-hydroxycholesterol-regulates-lysosome-amp-kinase-activation-and-metabolic-reprogramming-to-educate-immunosuppressive-macrophages
#4
JOURNAL ARTICLE
Jun Xiao, Shuang Wang, Longlong Chen, Xinyu Ding, Yuanhao Dang, Mingshun Han, Yuxiao Zheng, Huan Shen, Sifan Wu, Mingchang Wang, Dan Yang, Na Li, Chen Dong, Miao Hu, Chen Su, Weiyun Li, Lijian Hui, Youqiong Ye, Huiru Tang, Bin Wei, Hongyan Wang
Macrophages are critical to turn noninflamed "cold tumors" into inflamed "hot tumors". Emerging evidence indicates abnormal cholesterol metabolites in the tumor microenvironment (TME) with unclear function. Here, we uncovered the inducible expression of cholesterol-25-hydroxylase (Ch25h) by interleukin-4 (IL-4) and interleukin-13 (IL-13) via the transcription factor STAT6, causing 25-hydroxycholesterol (25HC) accumulation. scRNA-seq analysis confirmed that CH25Hhi subsets were enriched in immunosuppressive macrophage subsets and correlated to lower survival rates in pan-cancers...
April 12, 2024: Immunity
https://read.qxmd.com/read/38640901/mettl3-melting-the-tumor-microenvironment-for-improved-immunotherapy
#5
JOURNAL ARTICLE
Longfei Gao, Lei Ding
The tumor microenvironment (TME) dictates the outcome of cancer immunotherapy. In this issue of Cell Chemical Biology, Yu et al.1 report that targeting Mettl3 leads to a more inflamed, "hot" TME and effective anti-PD-1 therapy. This study points to a new target in remodeling the TME for improved immunotherapy.
April 18, 2024: Cell Chemical Biology
https://read.qxmd.com/read/38631711/spatial-comparison-of-molecular-features-associated-with-resistance-to-pembrolizumab-in-bcg-unresponsive-bladder-cancer
#6
JOURNAL ARTICLE
Khyati Meghani, Noah Frydenlund, Yanni Yu, Bonnie Choy, Joshua J Meeks
Intravenous immune checkpoint inhibition achieves a 40% 3-month response in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ. Yet, only half of the early responders will continue to be disease-free by 12 months, and resistance mechanisms are poorly defined. We performed spatial profiling of BCG-unresponsive tumors from patients responsive or resistant to intravenous pembrolizumab treatment, analyzing samples both before initiating and 3 months post-intravenous pembrolizumab treatment...
April 16, 2024: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/38631706/tumor-targeted-therapy-with-braf-inhibitor-recruits-activated-dendritic-cells-to-promote-tumor-immunity-in-melanoma
#7
JOURNAL ARTICLE
Florian Hornsteiner, Janine Vierthaler, Helen Strandt, Antonia Resag, Zhe Fu, Markus Ausserhofer, Christoph H Tripp, Sophie Dieckmann, Markus Kanduth, Kathryn Farrand, Sarah Bregar, Niloofar Nemati, Natascha Hermann-Kleiter, Athanasios Seretis, Sudhir Morla, David Mullins, Francesca Finotello, Zlatko Trajanoski, Guido Wollmann, Franca Ronchese, Marc Schmitz, Ian F Hermans, Patrizia Stoitzner
BACKGROUND: Tumor-targeted therapy causes impressive tumor regression, but the emergence of resistance limits long-term survival benefits in patients. Little information is available on the role of the myeloid cell network, especially dendritic cells (DC) during tumor-targeted therapy. METHODS: Here, we investigated therapy-mediated immunological alterations in the tumor microenvironment (TME) and tumor-draining lymph nodes (LN) in the D4M.3A preclinical melanoma mouse model (harboring the V-Raf murine sarcoma viral oncogene homolog B (BRAF)V600E mutation) by using high-dimensional multicolor flow cytometry in combination with multiplex immunohistochemistry...
April 17, 2024: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/38625857/biophysical-characterization-of-the-cxc-chemokine-receptor-2-ligands
#8
JOURNAL ARTICLE
Patrick Martin, Emily A Kurth, David Budean, Nathalie Momplaisir, Elaine Qu, Jennifer M Simien, Grace E Orellana, Chad A Brautigam, Alan V Smrcka, Ellinor Haglund
The chemokines of the immune system act as first responders by operating as chemoattractants, directing immune cells to specific locations of inflamed tissues. This promiscuous network is comprised of 50 ligands and 18 receptors where the ligands may interact with the receptors in various oligomeric states i.e., monomers, homodimers, and heterodimers. Chemokine receptors are G-protein coupled receptors (GPCRs) present in the membrane of immune cells. The migration of immune cells occurs in response to a concentration gradient of the ligands...
2024: PloS One
https://read.qxmd.com/read/38615618/dna-nanodevice-as-a-multi-module-co-delivery-platform-for-combination-cancer-immunotherapy
#9
JOURNAL ARTICLE
Cunpeng Nie, Jingxuan Ye, Jian-Hui Jiang, Xia Chu
A major challenge in combining cancer immunotherapy is the efficient delivery of multiple types of immunological stimulators to elicit a robust anti-tumor immune response and reprogram the immunosuppressive tumor microenvironment (TME). Here, we developed a DNA nanodevice that was generated by precisely assembling three types of immunological stimulators. The doxorubicin (Dox) component induced immunogenic cell death (ICD) in tumor cells and enhanced phagocytosis of antigen-presenting cells (APCs). Exogenous double-stranded DNA (dsDNA) could act as a molecular adjuvant to activate the stimulator of interferon genes (STING) signaling in APCs by engulfing dying tumor cells...
April 13, 2024: Journal of Colloid and Interface Science
https://read.qxmd.com/read/38613910/subtyping-of-triple-negative-breast-cancers-its-prognostication-and-implications-in-diagnosis-of-breast-origin
#10
JOURNAL ARTICLE
H Hu, K Tong, J Y Tsang, C W Ko, F Tam, T C Loong, G M Tse
BACKGROUND: Triple-negative breast cancer (TNBC) subtyping by gene profiling has provided valuable clinical information. Here, we aimed to evaluate the relevance of TNBC subtyping using immunohistochemistry (IHC), which could be a more clinically practical approach, for prognostication and applications in patient management. METHODS: A total of 123 TNBC cases were classified using androgen receptor (AR), CD8, Forkhead box C1 protein (FOXC1), and doublecortin-like kinase 1 (DCLK1) into luminal androgen receptor (LAR), basal-like immunosuppressive (BLIS), mesenchymal-like (MES), and immunomodulatory (IM) subtypes...
April 12, 2024: ESMO Open
https://read.qxmd.com/read/38579729/inflammatory-and-subtype-dependent-serum-protein-signatures-predict-survival-beyond-the-ctdna-in-aggressive-b-cell-lymphomas
#11
JOURNAL ARTICLE
Maare Arffman, Leo Meriranta, Matias Autio, Harald Holte, Judit Jørgensen, Peter Brown, Sirkku Jyrkkiö, Mats Jerkeman, Kristina Drott, Øystein Fluge, Magnus Björkholm, Marja-Liisa Karjalainen-Lindsberg, Klaus Beiske, Mette Ølgod Pedersen, Suvi-Katri Leivonen, Sirpa Leppä
BACKGROUND: Biological heterogeneity of large B cell lymphomas (LBCLs) is poorly captured by current prognostic tools, hampering optimal treatment decisions. METHODS: We dissected the levels of 1,463 serum proteins in a uniformly treated trial cohort of 109 patients with high-risk primary LBCL (ClinicalTrials.gov: NCT01325194) and correlated the profiles with molecular data from tumor tissue and circulating tumor DNA (ctDNA) together with clinical data. FINDINGS: We discovered clinically and biologically relevant associations beyond established clinical estimates and ctDNA...
April 2, 2024: Med
https://read.qxmd.com/read/38568775/interactions-between-mdscs-and-the-autonomic-nervous-system-opportunities-and-challenges-in-cancer-neuroscience
#12
JOURNAL ARTICLE
Lin-Zhen Shu, Yi-Dan Ding, Jin-Yao Zhang, Rui-Shan He, Li Xiao, Bing-Xing Pan, Huan Deng
Myeloid-derived suppressor cells (MDSC) are a population of heterogeneous immune cells that are involved in precancerous conditions and neoplasms. The autonomic nervous system (ANS), which is composed of the sympathetic nervous system and the parasympathetic nervous system, is an important component of the tumor microenvironment that responds to changes in the internal and external environment mainly through adrenergic and cholinergic signaling. An abnormal increase of autonomic nerve density has been associated with cancer progression...
April 2, 2024: Cancer Immunology Research
https://read.qxmd.com/read/38562769/integrative-spatial-omics-reveals-distinct-tumor-promoting-multicellular-niches-and-immunosuppressive-mechanisms-in-african-american-and-european-american-patients-with-tnbc
#13
Qian Zhu, Akhila Balasubramanian, Jaya Ruth Asirvatham, Danthasinghe Waduge Badrajee Piyarathna, Jaspreet Kaur, Nada Mohamed, Ling Wu, Megha Chatterjee, Stacy Wang, Niloufar Pourfarrokh, Uttam Rasaily, Yitian Xu, Junjun Zheng, Deborah Jebakumar, Arundathi Rao, Shu-Hsia Chen, Yi Li, Eric Chang, Xiaoxian Li, Ritu Aneja, Xiang H-F Zhang, Arun Sreekumar
Racial disparities in triple-negative breast cancer (TNBC) outcomes have been reported. However, the biological mechanisms underlying these disparities remain unclear. We integrated imaging mass cytometry and spatial transcriptomics, to characterize the tumor microenvironment (TME) of African American (AA) and European American (EA) patients with TNBC. The TME in AA patients was characterized by interactions between endothelial cells, macrophages, and mesenchymal-like cells, which were associated with poor patient survival...
March 31, 2024: bioRxiv
https://read.qxmd.com/read/38558536/characterization-and-impact-of-non-canonical-wnt-signaling-on-outcomes-of-urothelial-carcinoma
#14
JOURNAL ARTICLE
Margaret Meagher, Harris Krause, Andrew Elliott, Alex Farrell, Emmanuel S Antonarakis, Bruno Bastos, Elisabeth I Heath, Christina Jamieson, Tyler F Stewart, Aditya Bagrodia, Chadi Nabhan, Matt Oberley, Rana R McKay, Amirali Salmasi
BACKGROUND: Non-canonical WNT family (WNT5A pathway) signaling via WNT5A through ROR1 and its partner, ROR2, or Frizzled2 (FZD2) is linked to processes driving tumorigenesis and therapy resistance. We utilized a large dataset of urothelial carcinoma (UC) tumors to characterize non-canonical WNT signaling through WNT5A, ROR1, ROR2, or FZD2 expression. METHODS: NextGen Sequencing of DNA (592 genes or WES)/RNA (WTS) was performed for 4125 UC tumors submitted to Caris Life Sciences...
April 2024: Cancer Medicine
https://read.qxmd.com/read/38553589/identification-of-mycn-non-amplified-neuroblastoma-subgroups-points-towards-molecular-signatures-for-precision-prognosis-and-therapy-stratification
#15
JOURNAL ARTICLE
Xiaoxiao Hu, Yilu Zhou, Charlotte Hill, Kai Chen, Cheng Cheng, Xiaowei Liu, Peiwen Duan, Yaoyao Gu, Yeming Wu, Rob M Ewing, Zhongrong Li, Zhixiang Wu, Yihua Wang
BACKGROUND: Despite the extensive study of MYCN-amplified neuroblastomas, there is a significant unmet clinical need in MYCN non-amplified cases. In particular, the extent of heterogeneity within the MYCN non-amplified population is unknown. METHODS: A total of 1566 samples from 16 datasets were identified in Gene Expression Omnibus (GEO) and ArrayExpress. Characterisation of the subtypes was analysed by ConsensusClusterPlus. Independent predictors for subgrouping were constructed from the single sample predictor based on the multiclassPairs package...
March 29, 2024: British Journal of Cancer
https://read.qxmd.com/read/38553264/evaluation-of-uro17%C3%A2-to-improve-non-invasive-detection-of-bladder-cancer
#16
JOURNAL ARTICLE
Sima P Porten, Elizabeth Y Wang, Poonam Vohra, Peter R Carroll, Sholeh Jahanfard, Nam W Kim
BACKGROUND: The gold standard for detecting bladder cancer is cystoscopy with biopsy or transurethral resection confirming histologic diagnosis. URO17® employs a chromogenically labeled monoclonal antibody to keratin 17 (k17), an intermediate filament cytoskeleton molecule associated with bladder, pancreatic, and cervical cancers. Preliminary studies evaluating k17 demonstrated a high sensitivity and specificity for the detection of bladder cancer, supporting the need for further study...
March 28, 2024: Urologic Oncology
https://read.qxmd.com/read/38550593/sting-agonist-inflames-the-cervical-cancer-immune-microenvironment-and-overcomes-anti-pd-1-therapy-resistance
#17
JOURNAL ARTICLE
Tianye Li, Weijiang Zhang, Mengke Niu, Yuze Wu, Xinyue Deng, Jianwei Zhou
BACKGROUND: Cervical cancer poses a significant global threat to women's health. However, current therapeutic interventions, such as radiotherapy, chemotherapy, surgical resection, and immune checkpoint inhibitors, face limitations in the advanced stages of the disease. Given the immunosuppressive microenvironment in cervical cancer, it is imperative to explore novel perspectives. In this regard, STING agonists have emerged as promising candidates. METHODS: The expression profiles and clinicopathological data were obtained from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38538258/the-prognostic-and-immune-significance-of-bzw2-in-pan-cancer-and-its-relationship-with-proliferation-and-apoptosis-of-cervical-cancer
#18
JOURNAL ARTICLE
Chaolin Li, Qin Li, Li Li, Siyu Sun, Xun Lei
BACKGROUND: Basic leucine zipper and W2 domains 2 ( BZW2 ), a member of the basic domain leucine zipper superfamily of transcription factors, has been implicated in the development and progression of various cancers. However, the precise biological role of BZW2 in pan-cancer datasets remains to be explored. This study aimed to assess the prognostic significance of BZW2 and its immune-related signatures in various tumors. METHODS: Our study investigated the expression, epigenetic modifications, and clinical prognostic relevance of BZW2 using multi-omics data in different cancer types...
March 11, 2024: Frontiers in Bioscience (Landmark Edition)
https://read.qxmd.com/read/38537936/a-deep-learning-based-assessment-pipeline-for-intraepithelial-and-stromal-tumor-infiltrating-lymphocytes-in-high-grade-serous-ovarian-carcinoma
#19
JOURNAL ARTICLE
Kohei Hamada, Ryusuke Murakami, Akihiko Ueda, Yoko Kashima, Chiho Miyagawa, Mana Taki, Koji Yamanoi, Ken Yamaguchi, Junzo Hamanishi, Sachiko Minamiguchi, Noriomi Matsumura, Masaki Mandai
Tumor-infiltrating lymphocytes (TILs) are associated with improved survival in patients with epithelial ovarian cancer. However, the evaluation of TILs has not been applied to routine clinical practice due to reproducibility issues. We developed two convolutional neural network models to detect TILs and to determine their spatial location in whole-slide images, and established a spatial assessment pipeline to objectively quantify intraepithelial and stromal TILs in patients with high-grade serous ovarian carcinoma...
March 25, 2024: American Journal of Pathology
https://read.qxmd.com/read/38525811/automated-tumor-immunophenotyping-predicts-clinical-benefit-from-anti-pd-l1-immunotherapy
#20
JOURNAL ARTICLE
Xiao Li, Jeffrey Eastham, Jennifer M Giltnane, Wei Zou, Andries Zijlstra, Evgeniy Tabatsky, Romain Banchereau, Ching-Wei Chang, Barzin Y Nabet, Namrata S Patil, Luciana Molinero, Steve Chui, Maureen Harryman, Shari Lau, Linda Rangell, Yannick Waumans, Mark Kockx, Darya Orlova, Hartmut Koeppen
Cancer immunotherapy has transformed the clinical approach to patients with malignancies, as profound benefits can be seen in a subset of patients. To identify this subset, biomarker analyses increasingly focus on phenotypic and functional evaluation of the tumor microenvironment to determine if density, spatial distribution, and cellular composition of immune cell infiltrates can provide prognostic and/or predictive information. Attempts have been made to develop standardized methods to evaluate immune infiltrates in the routine assessment of certain tumor types; however, broad adoption of this approach in clinical decision-making is still missing...
March 25, 2024: Journal of Pathology
keyword
keyword
112149
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.